Journal of Current Hematology & Oncology Research

Letter to the Editor

DOI: 10.51271/JCHOR-0050

A comment on 'The relationship between hepatocellular carcinoma and resolvin D1' by Erdin et al.

İbrahim Ethem Güven

Department of Gastroenterology, Yenimahalle Training and Research Hospital, Ankara, Turkiye

Cite this article: Güven İE. The relationship between hepatocellular carcinoma and resolvin D1. *J Curr Hematol Oncol Res.* 2024;2(4):100.

Corresponding Author: İbrahim Ethem Güven, drethemg@gmail.com

Received: 27/10/2024 ◆ **Accepted**: 11/11/2024 ◆ **Published**: 14/11/2024

Keywords: Letter to the editor, hepatocellular carcinoma, resolvin D1

Dear Editor,

We read the article entitled "The relationship between hepatocellular carcinoma and resolvin D1" by Erdin et al.[1] with great interest. First of all, we congratulate the authors and editorial board for this informative and interesting article.

In this study, they reported that resolvin D1 levels were significantly different between the control and cirrhosis group, and between the control and HCC group. Resolvin D1 levels were also found to be higher in the control group and lowest in the HCC group. In addition, a negative correlation was demonstrated between the resolvin D1 and AFP levels. Notably, resolvin D1 levels were negatively correlated with tumor stage.

In recent years, the effect of resolvin D1 on the anti-inflammatory process has been of interest. It has been demonstrated that resolvin D1 can play a significant role in the inhibition of tumor proliferation, metastasis, and epithelial-mesenchymal transition.[2] The underlying mechanism is thought to be a decrease in leukocyte infiltration, increased release of anti-inflammatory cytokines, and induction of leukocyte apoptosis.[3] In this concept, the low level of resolvin D1 in the HCC group shown in this study is promising for HCC screening in combination with AFP in cirrhotic patients. However, we believe that the sample size is relatively small for the evaluation of the association of resolvin D1 with tumor stage. Thus, a prospective study with larger sample size could provide more definitive data.

Overall, this study by Erdin et al.[1] demonstrated that resolvin D1 may be a useful biomarker for predicting the HCC as an alternative to AFP. Further studies are warranted on this topic.

ETHICAL DECLARATIONS

Referee Evaluation Process

Externally peer-reviewed.

Conflict of Interest Statement

The author have no conflicts of interest to declare.

Financial Disclosure

The author declared that this study has received no financial support.

Author Contributions

The author made the design, execution, and analysis of the paper, and that they have approved the final version.

REFERENCES

1. Erdin Z, Gül Ö, Ergül B, et al. The relationship between hepatocellular carcinoma and resolvin D1. *J Curr Hematol Oncol Res*. 2023;1(4):96-101.
2. Yang M, Song XQ, Han M, et al. The role of resolvin D1 in liver diseases. *Prostaglandins Other Lipid Mediat*. 2022;160:106634.
3. Li J, Deng X, Wang S, et al. Resolvin D1 attenuates CCl4 induced liver fibrosis by inhibiting autophagy-mediated HSC activation via AKT/mTOR pathway. *Front Pharmacol*. 2021;12:792414.

This work is licensed under a Creative Commons Attribution 4.0 International License.